HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER
Clinical trials for HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER explained in plain language.
Never miss a new study
Get alerted when new HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER trials appear
Sign up with your email to follow new studies for HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill could fight bladder cancer when standard therapy fails
Disease control CompletedThis phase 2 trial tested a daily pill called erdafitinib against standard chemotherapy for people with a high-risk bladder cancer that returned after BCG treatment. The study enrolled 107 participants whose tumors have specific FGFR gene changes. The goal was to see if erdafitin…
Matched conditions: HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER
Phase: PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Immunotherapy drug shows promise for tough bladder cancer cases
Disease control CompletedThis phase II trial tested the immunotherapy drug pembrolizumab (Keytruda) alone or with another agent in 296 people with high-risk non-muscle-invasive bladder cancer that did not respond to standard BCG therapy. Participants received the drug intravenously every three weeks. The…
Matched conditions: HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC